Next Article in Journal
Systems Biology Approaches Reveal Potential Phenotype-Modifier Genes in Neurofibromatosis Type 1
Next Article in Special Issue
Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine
Previous Article in Journal
Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives
Previous Article in Special Issue
PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
Article

Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2

1
Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy
2
Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy
*
Author to whom correspondence should be addressed.
Daniele Fanale, Lorena Incorvaia and Clarissa Filorizzo contributed equally to this work.
Giuseppe Badalamenti, Antonio Russo and Viviana Bazan are co-last authors.
Cancers 2020, 12(9), 2415; https://doi.org/10.3390/cancers12092415
Received: 23 July 2020 / Revised: 23 August 2020 / Accepted: 24 August 2020 / Published: 25 August 2020
Many bilateral breast cancer patients with increased hereditary susceptibility to breast cancer result negative for BRCA1 or BRCA2 pathogenic variants and, thus, need a further genetic testing through a broader gene panel. Some patients with negative test result for BRCA1/2 pathogenic variants may harbor pathogenic variants in other breast cancer susceptibility genes, including ATM, CHEK2, PALB2, PTEN, TP53. Of course, the use of a multi-gene panel provides clinicians more information through a single test. Therefore, we focused on potential clinical impact of a NGS-based multi-gene panel testing in bilateral breast cancer patients, in order to evaluate the utility of perform a most comprehensive genetic analysis in these subjects, regardless the criteria concerning personal and family history of cancer established by the current guidelines. Our study revealed that the use of a NGS-based multiple-gene panel testing could increase the detection rates of germline alterations in bilateral breast cancer patients.
Patients with unilateral breast cancer (UBC) have an increased risk of developing bilateral breast cancer (BBC). The annual risk of contralateral BC is about 0.5%, but increases by up to 3% in BRCA1 or BRCA2 pathogenic variant (PV) carriers. Our study was aimed to evaluate whether all BBC patients should be offered multi-gene panel testing, regardless their cancer family history and age at diagnosis. We retrospectively collected all clinical information of 139 BBC patients genetically tested for germline PVs in different cancer susceptibility genes by NGS-based multi-gene panel testing. Our investigation revealed that 52 (37.4%) out of 139 BBC patients harbored germline PVs in high- and intermediate-penetrance breast cancer (BC) susceptibility genes including BRCA1, BRCA2, PTEN, PALB2, CHEK2, ATM, RAD51C. Nineteen out of 53 positively tested patients harbored a PV in a known BC susceptibility gene (no-BRCA). Interestingly, in the absence of an analysis performed via multi-gene panel, a significant proportion (14.4%) of PVs would have been lost. Therefore, offering a NGS-based multi-gene panel testing to all BBC patients may significantly increase the detection rates of germline PVs in other cancer susceptibility genes beyond BRCA1/2, avoiding underestimation of the number of individuals affected by a hereditary tumor syndrome. View Full-Text
Keywords: ATM; BRCA1; BRCA2; breast cancer; bilateral breast cancer; CHECK2; germline pathogenic variants; multi-gene panel testing; PALB2; PTEN ATM; BRCA1; BRCA2; breast cancer; bilateral breast cancer; CHECK2; germline pathogenic variants; multi-gene panel testing; PALB2; PTEN
Show Figures

Figure 1

MDPI and ACS Style

Fanale, D.; Incorvaia, L.; Filorizzo, C.; Bono, M.; Fiorino, A.; Calò, V.; Brando, C.; Corsini, L.R.; Barraco, N.; Badalamenti, G.; Russo, A.; Bazan, V. Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2. Cancers 2020, 12, 2415. https://doi.org/10.3390/cancers12092415

AMA Style

Fanale D, Incorvaia L, Filorizzo C, Bono M, Fiorino A, Calò V, Brando C, Corsini LR, Barraco N, Badalamenti G, Russo A, Bazan V. Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2. Cancers. 2020; 12(9):2415. https://doi.org/10.3390/cancers12092415

Chicago/Turabian Style

Fanale, Daniele, Lorena Incorvaia, Clarissa Filorizzo, Marco Bono, Alessia Fiorino, Valentina Calò, Chiara Brando, Lidia R. Corsini, Nadia Barraco, Giuseppe Badalamenti, Antonio Russo, and Viviana Bazan. 2020. "Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2" Cancers 12, no. 9: 2415. https://doi.org/10.3390/cancers12092415

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop